NERV Minerva Neurosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1598646 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,973.5%
TTM EPS YoY-1,728.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-460.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets187.3%
Debt / equity—
Current ratio33.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-410.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.16M | $7.19M | $5.25M | $2.17M | $925,377 | $1.30M | $1.36M | $1.98M |
| SG&A expense | $4.28M | $3.45M | $11.42M | $2.81M | $1.92M | $2.08M | $2.54M | $2.54M |
| Operating income | -$9.43M | -$10.64M | -$16.67M | -$4.98M | -$2.84M | -$3.37M | -$3.90M | -$4.52M |
| Net income | $100.75M | $17.47M | -$125.40M | -$283.67M | -$2.74M | -$3.26M | -$3.75M | -$4.27M |
| EBITDA | — | — | — | -$4.98M | -$2.84M | -$3.37M | -$3.90M | -$4.52M |
| EPS (basic) | 1.94 | 0.36 | -2.86 | — | -0.36 | -0.43 | -0.50 | — |
| EPS (diluted) | -0.19 | -0.14 | -2.86 | — | -0.36 | -0.43 | -0.50 | — |
| Weighted avg. shares (diluted) | 75.25M | 79.10M | 43.90M | — | 7.57M | 7.57M | 7.57M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.22M | $24.65M | $32.66M | $82.30M | $12.29M | $15.25M | $17.29M | $21.36M |
| Short-term investments | $56.73M | $50.62M | $45.41M | — | — | — | — | — |
| Current assets | $83.41M | $79.73M | $79.11M | $83.10M | $13.02M | $15.55M | $17.92M | $22.27M |
| PP&E, net | — | — | — | $0 | $1,360 | $2,721 | $4,081 | $5,442 |
| Goodwill | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M |
| Total assets | $98.28M | $95.09M | $94.03M | $97.97M | $28.09M | $30.42M | $32.80M | $37.14M |
| Current liabilities | $2.53M | $3.96M | $4.48M | $2.29M | $2.67M | $2.53M | $1.95M | $2.84M |
| Total liabilities | $184.06M | $296.65M | $343.08M | $233.76M | $62.67M | $62.53M | $61.95M | $62.84M |
| Shareholders' equity | -$97.52M | -$213.30M | -$254.01M | -$140.75M | -$34.58M | -$32.11M | -$29.15M | -$25.69M |
| Shares outstanding | 49.84M | 47.23M | 43.84M | 43.27M | 6.99M | 6.99M | 6.99M | 6.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.15M | -$13.34M | -$5.43M | -$4.48M | -$2.92M | -$2.04M | -$4.07M | -$5.17M |
| Investing cash flow | -$5.73M | -$4.83M | -$45.29M | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $9.44M | $10.17M | $1.08M | $74.50M | -$45,166 | $0 | $0 | — |
| Depreciation & amortization | — | — | — | $1,360 | $1,361 | $1,360 | $1,361 | $1,360 |
| Stock-based compensation | $3.21M | $2.27M | $8.71M | $459,028 | $272,897 | $298,218 | $297,229 | $249,650 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.